A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology-Reference-Cited by-同舟云学术

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology

Published:2009-12 Issue:3 Volume:115 Page:443-446
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Miller David Scott,Blessing John A.,Drake Richard D.,Higgins Robert,McMeekin D. Scott,Puneky Louis V.,Krasner Carolyn N.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference52 articles.

1. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer;Horton;Cancer Treatment Rep.,1978

2. A phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;Cancer Treatment Rep.,1979

3. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;J. Clin. Oncol.,1994

4. A phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study;Thigpen;Am. J. Clin. Oncol.,1984

5. A phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;Gynecol. Oncol.,1989

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case;Surgery and Oncology;2023-12-21

2. Evolution of systemic therapy for disseminated endometrial cancer: literature review;Malignant tumours;2023-06-21

3. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer;Gynecologic Oncology;2022-12

4. Advanced and recurrent endometrial cancer: State of the art and future perspectives;Critical Reviews in Oncology/Hematology;2022-12

5. Interdisciplinary approach to the management of patients with uterine cancer progression;Tumors of female reproductive system;2022-05-08